Skip to main content

FDA OKs heart drug at center of $13 billion deal for Peninsula company

MyoKardia, co-founded by a Stanford University professor, developed the drug as part of a portfolio of treatments for genetic heart conditions.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.